Home | All trials

[RDF data]
Trial NCT00000484

Resource URI: http://static.linkedct.org/resource/trials/NCT00000484
PropertyValue
linkedct:brief_title Treatment of Hypertension
linkedct:condition <http://static.linkedct.org/resource/condition/13668>
linkedct:condition <http://static.linkedct.org/resource/condition/2312>
linkedct:condition <http://static.linkedct.org/resource/condition/5702>
linkedct:condition <http://static.linkedct.org/resource/condition/6238>
linkedct:criteria Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.
linkedct:description BACKGROUND: This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 55 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 27, 1999
linkedct:id NCT00000484
rdfs:label Trial NCT00000484
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Heart, Lung, and Blood Institute (NHLBI)
linkedct:nct_id NCT00000484
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id 3
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/24397>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/29500>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/3664>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/50072>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/51151>
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/9122>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000484>
linkedct:phase Phase 3
linkedct:reference <http://static.linkedct.org/resource/reference/3188>
linkedct:reference <http://static.linkedct.org/resource/reference/3189>
linkedct:reference <http://static.linkedct.org/resource/reference/3190>
linkedct:reference <http://static.linkedct.org/resource/reference/3457>
linkedct:reference <http://static.linkedct.org/resource/reference/41407>
linkedct:reference <http://static.linkedct.org/resource/reference/42715>
linkedct:reference <http://static.linkedct.org/resource/reference/48272>
linkedct:source National Heart, Lung, and Blood Institute (NHLBI)
linkedct:start_date April 1966
linkedct:study_design Prevention, Randomized, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
rdf:type linkedct:trials
linkedct:verification_date January 2000